{'fraction_non_alphanumeric': 0.033632286995515695, 'fraction_numerical': 0.006726457399103139, 'mean_word_length': 5.714285714285714, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
SYNTHESIS OF NANOGEL CARRIERS FOR DELIVERY OF ACTIVE PHOSPHORYLATED NUCLEOSIDE ANALOGUES.

Effective in chemotherapy of cancer and viral infections nucleoside analogues are actually ‘prodrugs’, which must be first converted in vivo into nucleoside 5′-monophosphates and, finally, into the drugs active form, nucleoside 5′-triphosphates (NTPs). They efficiently terminate DNA synthesis and are cytotoxic for the proliferating cancer cells. However, therapeutic nucleoside analogues in form of 5′-triphosphates are considered too unstable as a drug form to be used directly in cancer chemotherapy. A new drug formulation, which is presented here, is based on NTPs encapsulated into the nanosized cross-linked cationic polymer network called Nanogel [1]. Previously, these carriers were proved to be useful for encapsulation of antisense oligonucleotides and low soluble hydrophobic drugs [2–3].